Kidney Cancer | Tumor

Higher BMI May Be Associated With Improved Overall Survival in Patients with Metastatic Kidney Cancer

April 22nd 2021, 6:00pm


Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.

Active Surveillance Occurs Frequently Versus Systemic Therapy for Metastatic Renal Cell Carcinoma

April 20th 2021, 9:00pm


Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Inlyta Shows Promise for Metastatic Clear Cell Renal Cell Carcinoma

April 19th 2021, 1:00pm


Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

NCCN Recommends Lenvima Plus Keytruda for First-Line Renal Cell Carcinoma: What Patients Should Know

April 9th 2021, 1:00pm


CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

FDA’s Fotivda Approval Provides Certain Patients With Kidney Cancer ‘Another Future Treatment Option’

March 24th 2021, 6:00pm


The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.

Recent News and Updates in Kidney Cancer

March 15th 2021, 9:00pm


In honor of Kidney Cancer Awareness Month, CURE® compiled some recent kidney cancer news and updates patients may have missed.

FDA Approves Fotivda for Kidney Cancer Subset

March 10th 2021, 9:04pm


The agency granted approval to Fotivda in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.

Cabometyx-Opdivo Is ‘One of the New Standards of Care’ in Treating Kidney Cancer Subtype

March 9th 2021, 10:00pm


The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

February 23rd 2021, 2:00pm


Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

Newly a Mom, Kayla Got a Cancer Diagnosis

February 23rd 2021, 12:30pm


In June 2020, Kayla Bulkley gave birth to her and her husband’s long-awaited baby girl, Jane. Within a month, Kayla was diagnosed with kidney cancer.